Corvus Pharmaceuticals (CRVS) Study update summary

Study design and patient population

• Phase 1 trial enrolled 72 patients with moderate-to-severe atopic dermatitis who failed at least one prior therapy.

• Patients were randomized to different dosing regimens of soquelitinib or placebo, with treatment periods of 28 or 56 days and follow-up up to 90 days.

• 35% of patients had received prior systemic therapy, including treatment-resistant cases.

Efficacy and safety results

• Dose-dependent efficacy observed, with up to 75% of patients achieving EASI 75 and 33% achieving IGA 0/1 at highest dose.

• Disease control was maintained during post-treatment follow-up, with no rebound or need for rescue medication.

• Comparable efficacy seen in patients with prior systemic therapy and the overall group.

• No significant safety issues or severe adverse events reported; adverse events were mild and similar to placebo.

Immunologic and biomarker findings

• Soquelitinib inhibits ITK, blocking Th2/Th17 function and cytokine secretion (IL-4, IL-5, IL-13, IL-17).

• Treatment increased persistent Treg cells and reduced Th17 cells, supporting immune rebalancing.

• Inhibition of JAK-STAT signaling observed, with upregulation of SOCS3 and reduction in JAK1/STAT6.

• Biomarker changes correlated with durable clinical responses and lack of disease rebound.